Kevin Haas - Dec 20, 2024 Form 3 Insider Report for Vincerx Pharma, Inc. (VINC)

Role
Acting Chief Financial Officer
Signature
By: /s/ Kevin Haas
Stock symbol
VINC
Transactions as of
Dec 20, 2024
Transactions value $
$0
Form type
3
Date filed
1/6/2025, 04:29 PM
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VINC Common Stock 42.8K Dec 20, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VINC Stock Option (right to buy) Dec 20, 2024 Common Stock 14.5K $0.55 Direct F1
holding VINC Stock Option (right to buy) Dec 20, 2024 Common Stock 19K $0.55 Direct F2
holding VINC Stock Option (right to buy) Dec 20, 2024 Common Stock 19K $0.55 Direct F3
holding VINC Stock Option (right to buy) Dec 20, 2024 Common Stock 27K $0.55 Direct F4
holding VINC Stock Option (right to buy) Dec 20, 2024 Common Stock 37.1K $0.55 Direct F5
holding VINC Stock Option (right to buy) Dec 20, 2024 Common Stock 27.9K $0.55 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third (1/3) vests on February 14, 2023, with the remainder vesting in twenty-four equal monthly installments thereafter.
F2 Option vests in twenty-four equal monthly installments starting from August 25, 2022.
F3 Option vests in twenty-four equal monthly installments starting from November 15, 2022.
F4 Option vests in twenty-four equal monthly installments starting from February 15, 2023.
F5 One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney